Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management

Abstract excerpt

Pregnancy-associated atypical hemolytic uremic syndrome is a systemic disease associated with high morbidity and mortality rates, caused by dysregulation of the alternative complement pathway, leading to uncontrolled complement activation resulting in thrombotic microangiopathy. This condition can be effectively treated by anti-C5 therapy, which controls complement activation. Treatment can be safely discontinued...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenosine and Purinergic Signaling
• Share to Complement system in diseases
• Share to Renal Diseases and Glomerulopathies